Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KRONOS BIO, INC.

(KRON)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Kronos Bio Says First Patient Dosed in Trial of Leukemia Treatment Entospletinib

12/06/2021 | 08:28am EST


ę MT Newswires 2021
All news about KRONOS BIO, INC.
01/14INSIDER BUY : Allogene Therapeutics
MT
2021KRONOS BIO, INC.(NASDAQGS : KRON) added to NASDAQ Biotechnology Index
CI
2021KRONOS BIO, INC.(NASDAQGS : KRON) added to S&P Biotechnology Select Industry Index
CI
2021Kronos Bio Says First Patient Dosed in Trial of Leukemia Treatment Entospletinib
MT
2021KRONOS BIO, INC. : Other Events (form 8-K)
AQ
2021Kronos Bio Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entosplet..
GL
2021Kronos Bio, Inc. Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Ent..
CI
2021Kronos Bio's Cancer Drug Candidate Shows Potential in Phase 1/2 Trial
MT
2021KRONOS BIO, INC. : Other Events (form 8-K)
AQ
2021Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor ..
GL
More news
Analyst Recommendations on KRONOS BIO, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -144 M - -
Net cash 2021 178 M - -
P/E ratio 2021 -3,51x
Yield 2021 -
Capitalization 538 M 538 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 95
Free-Float -
Chart KRONOS BIO, INC.
Duration : Period :
Kronos Bio, Inc. Technical Analysis Chart | KRON | US50107A1043 | MarketScreener
Technical analysis trends KRONOS BIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 9,54 $
Average target price 40,25 $
Spread / Average Target 322%
EPS Revisions
Managers and Directors
Norbert W. Bischofberger President, Chief Executive Officer & Director
Yasir B. Al-Wakeel CFO & Head-Corporate Development
Arie S. Belldegrun Chairman
Jorge DiMartino Chief Medical Officer & EVP-Clinical Development
Christopher Dinsmore Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
KRONOS BIO, INC.-29.80%538
MODERNA, INC.-34.04%67 921
LONZA GROUP AG-13.71%53 315
IQVIA HOLDINGS INC.-13.38%46 690
SEAGEN INC.-13.93%24 331
ICON PUBLIC LIMITED COMPANY-17.37%20 831